1. Home
  2. AZN
  3. AZN News

Latest AstraZeneca PLC (AZN) News on May 9, 2025

AZN

MT Newswires

5 hours ago

AstraZeneca's Imfinzi Combination Therapy Boosts Disease-Free Survival in Bladder Cancer Trial

IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial
AZN

Business Wire

7 hours ago

IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial

AstraZeneca and Daiichi’s Enhertu shows pCR rate improvement in breast cancer trial
AZN

Clinical Trials Arena

a day ago

AstraZeneca and Daiichi’s Enhertu shows pCR rate improvement in breast cancer trial

AstraZeneca (LSE:AZN) Reports Positive Phase 3 Trial Results For Breast Cancer Treatment
AZN

Simply Wall St.

2 days ago

AstraZeneca (LSE:AZN) Reports Positive Phase 3 Trial Results For Breast Cancer Treatment

AZN

MT Newswires

2 days ago

AstraZeneca Says Enhertu Followed by THP Improved Pathologic Complete Response Rate in Breast Cancer Study

AZN

Thomson Reuters StreetEvents

2 days ago

Q1 2025 Arcus Biosciences Inc Earnings Call

Expediting parallel drug approval pathways is challenging, but rewarding
AZN

Pharmaceutical Technology

2 days ago

Expediting parallel drug approval pathways is challenging, but rewarding

ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11
AZN

Business Wire

2 days ago

ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11

EC approves AstraZeneca’s Calquence combo to treat MCL
AZN

Pharmaceutical Technology

2 days ago

EC approves AstraZeneca’s Calquence combo to treat MCL

AZN

GuruFocus.com

2 days ago

Tempus AI Inc (TEM) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ...

AZN or ARGX: Which Is the Better Value Stock Right Now?
AZN

Zacks

3 days ago

AZN or ARGX: Which Is the Better Value Stock Right Now?

AstraZeneca's (LON:AZN) Earnings Offer More Than Meets The Eye
AZN

Simply Wall St.

3 days ago

AstraZeneca's (LON:AZN) Earnings Offer More Than Meets The Eye

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
AZN

Zacks

4 days ago

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

AstraZeneca First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
AZN

Simply Wall St.

5 days ago

AstraZeneca First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

AstraZeneca (LSE:AZN) Announces Positive Results From Breztri Trials For Uncontrolled Asthma
AZN

Simply Wall St.

7 days ago

AstraZeneca (LSE:AZN) Announces Positive Results From Breztri Trials For Uncontrolled Asthma

Here's what top C-suites are saying about tariffs
AZN

Yahoo Finance Video

7 days ago

Here's what top C-suites are saying about tariffs

AZN

MT Newswires

7 days ago

European Equities Close Sharply Higher in Friday Trading; Eurozone Inflation Unchanged at 2.2%

AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma
AZN

Benzinga

7 days ago

AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma

Think It's Too Late to Buy Tempus AI? Here's the Biggest Reason Why There's Still Time.
AZN

Motley Fool

7 days ago

Think It's Too Late to Buy Tempus AI? Here's the Biggest Reason Why There's Still Time.

Amgen's Q1 Earnings Beat Estimates, Key Drugs Drive Sales Growth
AZN

Zacks

7 days ago

Amgen's Q1 Earnings Beat Estimates, Key Drugs Drive Sales Growth

AZN

MT Newswires

7 days ago

Astrazeneca Asthma Treatment Study Meets Primary Endpoints

AstraZeneca’s triple-combo triumphs in two Phase III asthma trials
AZN

Clinical Trials Arena

7 days ago

AstraZeneca’s triple-combo triumphs in two Phase III asthma trials

BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma
AZN

Business Wire

7 days ago

BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma

'Declare victory and move on': Eli Lilly CEO on Trump tariff threat
AZN

Yahoo Finance

8 days ago

'Declare victory and move on': Eli Lilly CEO on Trump tariff threat

Ionis Q1 Earnings and Sales Top Estimates, Stock Gains on Raised '25 View
AZN

Zacks

8 days ago

Ionis Q1 Earnings and Sales Top Estimates, Stock Gains on Raised '25 View

AstraZeneca quietly exits neuroscience
AZN

BioPharma Dive

8 days ago

AstraZeneca quietly exits neuroscience

3 UK Stocks Estimated To Be 21.1% To 46.6% Below Intrinsic Value
AZN

Simply Wall St.

8 days ago

3 UK Stocks Estimated To Be 21.1% To 46.6% Below Intrinsic Value

Imfinzi approval positions AstraZeneca at forefront of perioperative MIBC
AZN

Clinical Trials Arena

9 days ago

Imfinzi approval positions AstraZeneca at forefront of perioperative MIBC

AstraZeneca’s Truqap fails in another Phase III trial
AZN

Pharmaceutical Technology

9 days ago

AstraZeneca’s Truqap fails in another Phase III trial

AstraZeneca PLC (AZN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Strategic ...
AZN

GuruFocus.com

9 days ago

AstraZeneca PLC (AZN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Strategic ...

AstraZeneca Tops Earnings Views And Shares Rise Despite Cancer Miss
AZN

Investor's Business Daily

10 days ago

AstraZeneca Tops Earnings Views And Shares Rise Despite Cancer Miss

AZN

Morningstar Research

10 days ago

Analyst Report: AstraZeneca PLC

AZN

MT Newswires

10 days ago

Sector Update: Health Care Stocks Gain Late Afternoon

AstraZeneca CEO calls for increased European investment in pharma
AZN

Pharmaceutical Technology

10 days ago

AstraZeneca CEO calls for increased European investment in pharma

AZN

MT Newswires

10 days ago

Sector Update: Health Care Stocks Higher Tuesday Afternoon

AZN

MT Newswires

10 days ago

Astrazeneca Does not Expect Material Long-Term Impact From US Tariffs, CEO Says

AstraZeneca Beat Earnings Views, But Sales Come In Light As Cancer Study Flops
AZN

Investor's Business Daily

10 days ago

AstraZeneca Beat Earnings Views, But Sales Come In Light As Cancer Study Flops

EsoBiotec to Present Preclinical Proof-of-Concept Data for Its Off-the-Shelf ENaBL In Vivo Cell Therapy Platform at the 28th Annual Meeting of the American Society of Gene and Cell Therapy
AZN

GlobeNewswire

10 days ago

EsoBiotec to Present Preclinical Proof-of-Concept Data for Its Off-the-Shelf ENaBL In Vivo Cell Therapy Platform at the 28th Annual Meeting of the American Society of Gene and Cell Therapy

AstraZeneca Sales, Earnings Rise; Warns of Mounting Legal Challenges in China
AZN

The Wall Street Journal

10 days ago

AstraZeneca Sales, Earnings Rise; Warns of Mounting Legal Challenges in China

AstraZeneca to keep 2025 forecast if US pharmaceutical tariffs in line with other sectors
AZN

Reuters

10 days ago

AstraZeneca to keep 2025 forecast if US pharmaceutical tariffs in line with other sectors

AZN

Associated Press Finance

10 days ago

Astrazeneca: Q1 Earnings Snapshot

AZN

MT Newswires

10 days ago

AstraZeneca's Q1 Core Earnings, Revenue Rise; Reaffirms 2025 Guidance

AstraZeneca's Q1 2025 Financial Results
AZN

Business Wire

10 days ago

AstraZeneca's Q1 2025 Financial Results

Coca-Cola earnings, JOLTS, Consumer Confidence: What to Watch
AZN

Yahoo Finance Video

11 days ago

Coca-Cola earnings, JOLTS, Consumer Confidence: What to Watch

The Zacks Analyst Blog Highlights Tempus AI, AstraZeneca, iRhythm Technologies and SOPHiA GENETICS
AZN

Zacks

14 days ago

The Zacks Analyst Blog Highlights Tempus AI, AstraZeneca, iRhythm Technologies and SOPHiA GENETICS

Tempus AI Stock Sees 21% Gain in 3 Days: Is it a Buy After AZN Deal?
AZN

Zacks

15 days ago

Tempus AI Stock Sees 21% Gain in 3 Days: Is it a Buy After AZN Deal?

Unveiling Astrazeneca (AZN) Q1 Outlook: Wall Street Estimates for Key Metrics
AZN

Zacks

15 days ago

Unveiling Astrazeneca (AZN) Q1 Outlook: Wall Street Estimates for Key Metrics

AstraZeneca enters $200m AI cancer pact with Tempus and Pathos
AZN

Pharmaceutical Technology

15 days ago

AstraZeneca enters $200m AI cancer pact with Tempus and Pathos

Can Biogen Keep the Beat Streak Alive This Earnings Season?
AZN

Zacks

15 days ago

Can Biogen Keep the Beat Streak Alive This Earnings Season?

AstraZeneca pushes EU to spend more on drugs amid Trump tariffs threat
AZN

The Telegraph

16 days ago

AstraZeneca pushes EU to spend more on drugs amid Trump tariffs threat

Why Tempus AI Stock Is Skyrocketing Today
AZN

Motley Fool

16 days ago

Why Tempus AI Stock Is Skyrocketing Today

AZN

MT Newswires

16 days ago

Tempus AI to Build Oncology Multimodal Foundation Model in Partnership With AstraZeneca, Pathos AI

Astrazeneca (AZN) Rises But Trails Market: What Investors Should Know
AZN

Zacks

17 days ago

Astrazeneca (AZN) Rises But Trails Market: What Investors Should Know

AstraZeneca rejoins leading U.S. drug lobby group after two-year absence
AZN

Reuters

17 days ago

AstraZeneca rejoins leading U.S. drug lobby group after two-year absence

Daiichi and AstraZeneca’s Enhertu shows PFS benefits in breast cancer trial
AZN

Clinical Trials Arena

17 days ago

Daiichi and AstraZeneca’s Enhertu shows PFS benefits in breast cancer trial

AZN

MT Newswires

17 days ago

Hutchmed Completes Patient Enrollment in Phase II Gastric Cancer Trial in China

Cellectis SA (CLLS) Q4 2024 Earnings Call Highlights: Strategic Collaborations and Financial ...
AZN

GuruFocus.com

18 days ago

Cellectis SA (CLLS) Q4 2024 Earnings Call Highlights: Strategic Collaborations and Financial ...

AstraZeneca (LSE:AZN) and Daiichi Sankyo's ENHERTU Shows Promising Results in HER2 Breast Cancer Trial
AZN

Simply Wall St.

18 days ago

AstraZeneca (LSE:AZN) and Daiichi Sankyo's ENHERTU Shows Promising Results in HER2 Breast Cancer Trial

Should You Buy, Sell or Hold AstraZeneca Stock Before Q1 Earnings?
AZN

Zacks

18 days ago

Should You Buy, Sell or Hold AstraZeneca Stock Before Q1 Earnings?

AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients
AZN

Benzinga

18 days ago

AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients

AZN

MT Newswires

18 days ago

AstraZeneca Says Breast Cancer Combination Therapy Shows Improvement in Progression-Free Survival

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy for patients with HER2+ metastatic breast cancer
AZN

Business Wire

18 days ago

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy for patients with HER2+ metastatic breast cancer

Lilly Soars After Weight-Loss Pill Results Rival Ozempic’s
AZN

Bloomberg

22 days ago

Lilly Soars After Weight-Loss Pill Results Rival Ozempic’s

Is AstraZeneca PLC (AZN) the Best Pharma Stock to Buy for Long Term Growth?
AZN

Insider Monkey

24 days ago

Is AstraZeneca PLC (AZN) the Best Pharma Stock to Buy for Long Term Growth?

Tariff wars to hit popular US-made drugs in China, regulator data shows
AZN

Reuters

24 days ago

Tariff wars to hit popular US-made drugs in China, regulator data shows

Is AstraZeneca (AZN) The Best UK Stock to Buy According to Billionaires?
AZN

Insider Monkey

25 days ago

Is AstraZeneca (AZN) The Best UK Stock to Buy According to Billionaires?

Nasdaq Bear Market: 3 Unstoppable Stocks You Can Buy With $300 Right Now
AZN

Motley Fool

25 days ago

Nasdaq Bear Market: 3 Unstoppable Stocks You Can Buy With $300 Right Now

The Zacks Analyst Blog AbbVie's, Rinvoq and AstraZeneca's and Novartis
AZN

Zacks

25 days ago

The Zacks Analyst Blog AbbVie's, Rinvoq and AstraZeneca's and Novartis

Pharma Stock Roundup: EU Nod to Expanded Use of ABBV, AZN Drugs & More
AZN

Zacks

a month ago

Pharma Stock Roundup: EU Nod to Expanded Use of ABBV, AZN Drugs & More

AstraZeneca’s oral breast cancer drug Truqap greenlit for NHS use
AZN

Pharmaceutical Technology

a month ago

AstraZeneca’s oral breast cancer drug Truqap greenlit for NHS use

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
AZN

Zacks

a month ago

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

AstraZeneca (LSE:AZN) Gains EU Approval For Breast Cancer Treatment DATROWAY
AZN

Simply Wall St.

a month ago

AstraZeneca (LSE:AZN) Gains EU Approval For Breast Cancer Treatment DATROWAY

Why Roche Holding, Eli Lilly, and AstraZeneca Stocks Dropped Today
AZN

Motley Fool

a month ago

Why Roche Holding, Eli Lilly, and AstraZeneca Stocks Dropped Today

Trump Says Pharmaceutical Tariffs Coming ‘Very Shortly’
AZN

Bloomberg

a month ago

Trump Says Pharmaceutical Tariffs Coming ‘Very Shortly’

3 No-Brainer Growth Stocks to Buy for Less Than $100
AZN

Motley Fool

a month ago

3 No-Brainer Growth Stocks to Buy for Less Than $100

Astrazeneca (AZN) Stock Moves -1.35%: What You Should Know
AZN

Zacks

a month ago

Astrazeneca (AZN) Stock Moves -1.35%: What You Should Know

AstraZeneca’s camizestrant gains momentum, but questions remain as first-line therapy
AZN

Clinical Trials Arena

a month ago

AstraZeneca’s camizestrant gains momentum, but questions remain as first-line therapy

AZN

Morningstar Research

a month ago

Analyst Report: AstraZeneca PLC

AZN Gets EU Nod for Expanded Use of Two Separate Cancer Drugs
AZN

Zacks

a month ago

AZN Gets EU Nod for Expanded Use of Two Separate Cancer Drugs

AZN

Argus Research

a month ago

Weekly Stock List

EC approves AstraZeneca’s Imfinzi combo for NSCLC
AZN

Pharmaceutical Technology

a month ago

EC approves AstraZeneca’s Imfinzi combo for NSCLC

AstraZeneca (LSE:AZN) Secures EU Approvals; $125 Million Payment Due to Daiichi Sankyo
AZN

Simply Wall St.

a month ago

AstraZeneca (LSE:AZN) Secures EU Approvals; $125 Million Payment Due to Daiichi Sankyo

European Drug Regulator Approves AstraZeneca's Two Flagship Cancer Drugs For Breast And Lung Cancer Settings
AZN

Benzinga

a month ago

European Drug Regulator Approves AstraZeneca's Two Flagship Cancer Drugs For Breast And Lung Cancer Settings

AZN

MT Newswires

a month ago

European Equities Spiral in Friday Trading Amid Global Selloff Sparked by US Tariffs

Daiichi and AstraZeneca’s Enhertu gains EC approval for breast cancers
AZN

Pharmaceutical Technology

a month ago

Daiichi and AstraZeneca’s Enhertu gains EC approval for breast cancers

Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits Failure
AZN

Zacks

a month ago

Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits Failure

AstraZeneca PLC's (LON:AZN) Stock Has Fared Decently: Is the Market Following Strong Financials?
AZN

Simply Wall St.

a month ago

AstraZeneca PLC's (LON:AZN) Stock Has Fared Decently: Is the Market Following Strong Financials?

AZN

MT Newswires

a month ago

Astrazeneca Says Imfinzi Approved in Europe for Operable Non-Small Cell Lung Cancer

Spirits, Swiss Watches, Sneakers: Global Stock-Market Winners and Losers from Tariffs
AZN

The Wall Street Journal

a month ago

Spirits, Swiss Watches, Sneakers: Global Stock-Market Winners and Losers from Tariffs

AZN

Thomson Reuters StreetEvents

a month ago

Q4 2024 AIM ImmunoTech Inc Earnings Call

AstraZeneca says AZD0780 demonstrates significant LDL-C reduction in trial
AZN

TipRanks

a month ago

AstraZeneca says AZD0780 demonstrates significant LDL-C reduction in trial

AstraZeneca's Imfinzi Gets FDA Nod for Bladder Cancer Indication
AZN

Zacks

a month ago

AstraZeneca's Imfinzi Gets FDA Nod for Bladder Cancer Indication

AstraZeneca’s AZD0780 cuts LDL-C by 50% in Phase IIb trial
AZN

Clinical Trials Arena

a month ago

AstraZeneca’s AZD0780 cuts LDL-C by 50% in Phase IIb trial

FDA approves AstraZeneca’s Imfinzi combo for bladder cancer
AZN

Pharmaceutical Technology

a month ago

FDA approves AstraZeneca’s Imfinzi combo for bladder cancer

Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol?
AZN

Investor's Business Daily

a month ago

Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol?

FDA Approves AstraZeneca's Imfinzi As First Perioperative Immunotherapy For Muscle-Invasive Bladder Cancer Patients
AZN

Benzinga

a month ago

FDA Approves AstraZeneca's Imfinzi As First Perioperative Immunotherapy For Muscle-Invasive Bladder Cancer Patients

AZN

MT Newswires

a month ago

AstraZeneca Says Investigational Drug Cuts LDL Cholesterol in Phase 2b Trial

​​AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial
AZN

Business Wire

a month ago

​​AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial

JNJ's Rybrevant-Lazcluze Combo Outshines AZN's Tagrisso in Lung Cancer
AZN

Zacks

a month ago

JNJ's Rybrevant-Lazcluze Combo Outshines AZN's Tagrisso in Lung Cancer

Stocks to Watch Monday: Nvidia, Tesla, Moderna, Stellantis
AZN

The Wall Street Journal

a month ago

Stocks to Watch Monday: Nvidia, Tesla, Moderna, Stellantis

Share on Social Networks: